Navigation Links
MicroPhage Selects Lynn Taussig, MD for Board of Directors

LONGMONT, Colo., Dec. 2 /PRNewswire/ -- MicroPhage, Inc.,, announced today that Lynn M. Taussig, MD has joined the company's Board of Directors. Taussig was president and CEO of National Jewish Medical and Research Center in Denver, the nation's leading institution for studying respiratory diseases, from 1993 to 2006. His medical specialty is pediatric pulmonology.

"I have followed MicroPhage extensively and am impressed with its progress in developing new, rapid bacterial identification and antibiotic susceptibility tests, and am enthused about the clinical impact their products will have in providing accurate and cost-effective diagnosis of serious infections," said Taussig.

MicroPhage CEO Steve Lundy knows Taussig's expertise in diagnosis and management of respiratory diseases and his healthcare management experience will be valuable to the board in guiding the company's future. "We are pleased to have a physician and hospital executive of Dr. Taussig's stature join our board. His involvement and support shows confidence in MicroPhage, and his clinical expertise and vision will be deeply valued," said Lundy.

Taussig has served on numerous academic, government and business boards and commissions and has authored more than 170 publications related to respiratory illnesses in children. He has earned several academic, civic and professional honors, including the Distinguished Achievement Award from the American Thoracic Society. He currently serves as special advisor to the Provost for Life Sciences at the University of Denver and is on the Board of Directors of the Colorado Biosciences Association.

MicroPhage is in late stage development for its bacterial detection and susceptibility diagnostic system. The first products are targeted for rapid detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive Staphylococcus aureus) for screening and diagnostic applications.

About MicroPhage

Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its bacteriophage-based amplification platform for immunoassay diagnostics, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive bacterial identification and antibiotic susceptibility testing. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testing, and are designed to fit the demands for improving laboratory workflow. For further information, go to

SOURCE MicroPhage
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Research Shows MicroPhage Test Accurately and Rapidly Detects Serious Bacterial Infections
2. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
3. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
4. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
5. West Penn Allegheny Health System Selects Electronic Health Record From Allscripts
6. ABMS Selects Kevin B. Weiss, MD, MPH, as New President and CEO
7. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
8. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
9. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
10. Delhaize Group Selects Trintechs AssureNET GL to Improve Compliance Process Efficiency
11. Financial Times Selects CAMFED International for 2007 Reader Seasonal Appeal
Post Your Comments:
(Date:12/1/2015)... ... ... Hospital Tampa is the first health care provider in the region to offer the ... is a vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult ... least 40 to 45 kg, or a BMI of at least 35 to 39.9 kg ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Dr. Paul Vitenas, ... Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single Physician Practice ... best among the many elite aesthetic physicians honored by the industry publication. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Annual 2015 Golden Bridge Business Awards under the New Products and Services category ... web based sample management software that helps labs organize data and ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been awarded a fixed price per sprint agile development contract to support ... $34 million over five years, provides software engineering, infrastructure, as well as operations ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VANCOUVER , Dec. 1, 2015  Following an ... (NASDAQ: OGXI ) announced today that its Phase ... interim futility analysis of the intent-to-treat (ITT) population. In ... identified by the DMC. Both the DMC and OncoGenex ... expected in the second half of 2016, depending on ...
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
Breaking Medicine Technology: